Market Insights & Fundamental Drivers

• Goldman Sachs Initiation: On April 17, 2026, Goldman Sachs initiated coverage with a Buy rating and a price target of $40.00. They cited the massive potential of soquelitinib in the atopic dermatitis market, projected to exceed $24 billion by 2035.
  
• Clinical Narrative: Confidence in the lead asset, soquelitinib, has increased significantly, with projected market penetration raised from 10% to 30%. Management is advancing the drug across multiple indications, including hidradenitis suppurativa and asthma (Phase 2 expected late 2026).
  
• Financial Health: While not yet profitable (expected EPS Q1: -$0.15), Corvus recently filed a mixed shelf offering, providing the "cash runway" necessary to fund upcoming Phase 2 and Phase 3 clinical trials.
  

Technical Analysis (TA)

• Momentum: The stock surged over 11% on Friday, April 17, following the analyst upgrade, closing at $16.74. This breakout successfully tested and held the 50-day Moving Average for the first time in a month.
  
• Support & Resistance:
  
  • Resistance: $21.82 (Median target), $26.95 (52-week high), $40.00 (target).
    
  • Support: $15.08 (50-DMA), $15.04 (Previous close), $14.38 (Weekly low).
    
• Indicators: The RSI (14) sits at 48.5, indicating the stock is far from overbought despite the recent jump. The MACD (0.14) has issued a Buy signal, confirming the shift in trend.
  

 Entry Timing & Strategic Note

• Entry Timing: Buy / Accumulate on Breakout. The stock has successfully reclaimed its key moving averages. The current price of $16.74 offers significant upside relative to the consensus target of $33.33 (approx. 99% upside).
  
• Strategy: This is a high-conviction biotech growth play. The "Smart Money" is moving in, and with the next earnings report on May 7, early positioning may capture the momentum leading into clinical updates.
  

Total Score (Weighted): 7.6 / 10
Verdict: STRONG BUY

GPRK is a special case: it’s a relatively small oil and gas company ($608M market cap) from Colombia/Latin America, which means platforms like Danelfin, Tradestie, and Holly AI do not cover it. As a result, the available scores are less complete than for stocks like NVDA or ON.
What the analysis does show is notably positive:
the stock surged +15% in a single day on April 10, on volume 3x the average. The Q4 EPS surprise came in at +115% above expectations. The $107M PIPE from Grupo Gilinski adds confidence — those shares have an 18-month lock-up, so Gilinski isn’t going anywhere.
The bull case for the next 1–5 days: with RSI around ~64 (not yet overbought), strong technicals, and momentum as a catalyst, there is room to push toward $10.34 (52-week high) and then the analyst median of $10.70. A cautious long position is justifiable.
The major risk is the proxy battle: Parex Resources is nominating 6 board candidates for the 2026 AGM. This could cause price volatility in both directions.
Technical Scores
Technical Score: Strong Buy
 RSI 64 neutral
Trendline:
Upward (daily)
Monthly: selling pressure present
Entry Timing:
Favorable now
RSI 64 — room for further upside
Options Score:
Limited
Low options volume (micro-cap)

🔍 MarketScreener & AI Insights:

• AI & Advanced Packaging: $ONTO's stock price is currently driven by the massive demand for Advanced Packaging and AI chips. The integration of "Dragonfly" inspection systems and the recent Semilab deal are fueling positive sentiment.
  
• Analyst Consensus: According to MarketScreener, the consensus is a "Strong Buy." The average price target was recently raised to $265.71, suggesting an upside potential of approximately 23% from the current price (~$215.53).
  
• AI-Alpha: Danelfin issues a "Hold" rating (6/10) but notes that the stock has a 57.36% probability of outperforming the S&P 500 over the next 3 months. The most positive AI signal stems from analyst Sentiment (+2.90%).
  

📈 Technical Confirmation:

• Momentum: The stock exhibits a very strong technical setup. All moving averages (MA5 through MA200) indicate a Strong Buy signal.
  
• RSI (14): The RSI stands at 61.65. This indicates powerful bullish momentum but leaves enough room before the stock becomes "overbought" (>70).
  
• MACD: The MACD level is at 1.90, confirming an active buy signal.
  
• Pivot Points:
  
  • Resistance: $225.33 (52-week high), $239.30 (Average analyst target).
    
  • Support: $214.65 (5-day average), $196.89 (Psychological floor).
    

📋 Strategic Note:$ONTO is a "pick-and-shovel" play in the AI revolution. While Nvidia manufactures the chips, Onto provides the quality control. Although AI scores (SST) remain at "Hold" due to high valuation (P/E ~78x), the technical momentum is strong enough that a further climb toward $250 - $265 is highly likely leading up to the May earnings.
Verdict: BUY (Focus on Momentum)

Short-Term Investment Outlook – Netflix (NFLX)Recommendation: Neutral to Moderately Bullish (Short-Term)
Time Horizon: 1–4 weeks

Technical AnalysisNetflix has shown strong upward momentum in recent sessions, supported by consistent higher highs and higher lows. The stock is currently trading above key moving averages, indicating a short-term bullish trend.

• Support Levels: Recent consolidation zones may act as support on pullbacks.
• Resistance Levels: Near-term resistance is likely around recent swing highs; a breakout could trigger further upside momentum.
• Indicators: RSI is approaching overbought territory, suggesting a possible short-term pullback or consolidation before continuation.

Catalysts

• Continued positive sentiment around subscriber growth and content performance
• Broader strength in tech and growth stocks
• Any news related to earnings guidance or strategic partnerships

Risks

• Short-term overbought conditions increasing the likelihood of a pullback
• Market-wide volatility, especially in tech stocks
• Negative sentiment or unexpected news impacting streaming competition

Strategy

• Aggressive traders: Consider buying on minor pullbacks toward support levels
• Conservative traders: Wait for a confirmed breakout above resistance with volume
• Risk management: Tight stop-loss below recent support is recommended

ConclusionNetflix Inc. remains technically strong in the short term, but traders should be cautious of overextended conditions. A buy-on-dip strategy or breakout confirmation approach is advisable.

🟢 Guardian Pharmacy Services ($GRDN)
Rating: Strong Buy
Sector: Healthcare (Pharmacy Management)
Top Pick
Guardian Pharmacy Services delivered a standout performance on March 11, reporting an earnings per share (EPS) beat of +42%, significantly exceeding market expectations. Current AI-driven analysis indicates a high probability of continued upside momentum.
SST Score: 8/10 (Buy)
Ensemble Score: 14/15 (Very Bullish)
LSTM Score: 13/15 (Momentum Play)
Signal: Strong Buy
Price Target: $32.00
(Recently upgraded following earnings)
Strategic Outlook:
Organic growth within long-term care facilities is accelerating, reinforcing the company’s expansion trajectory. From a technical perspective, momentum remains exceptionally strong following last week’s confirmed breakout.
Earnings Date: March 11, 2026 🟢
(Reported – Strong Beat)

Why TERN Is a Top Swing Trade This Week Institutional Buying – The Boxer Capital EntryRecent 13F filings show that Boxer Capital Management initiated a new position of 375,000 shares (~$15 million).
Institutional accumulation ahead of an earnings event (March 19) is often interpreted as a strong bullish signal, suggesting large investors expect positive developments.

Analyst Optimism and Price Target UpgradesRecent weeks have seen significant upward revisions in analyst expectations.
Key highlights:

• Zacks Investment Research Rank #2 (Buy) – placing TERN in the top 20% of stocks based on earnings revisions.
  
• Average price target: $58.13
  
• Bullish outlier target: $73.50
  

Even while the broader healthcare sector shows mixed performance, TERN continues to display “Stage 2 momentum”, indicating a strong and sustained uptrend.

 Technical SetupPrice Action

• Friday close (March 13): $46.52
  
• +5% gain on the day
  

Support & Resistance

• 52-week high: $48.26
  
• A breakout above $48.30 could trigger a major technical breakout.
  

Volume

• 4.2 million shares traded on Friday
  
• Nearly double the average volume, suggesting active accumulation by institutional investors.
  

Trading Plan (TERN)Overall Rating: STRONG BUY
Terns Pharmaceuticals is currently one of the hottest biotech momentum plays, driven by the dual catalysts of the obesity drug market and CML treatment development.
Suggested StrategyEntry Options

• Buy breakout above $48.30 (new high)
  
• Or accumulate on a dip near $45.50
  

Price Target

• $58.00 short-term (analyst consensus)
  

Stop Loss

• $41.50 (below last week’s low)
  

Bottom Line:
TERN combines strong clinical catalysts, institutional accumulation, bullish analyst sentiment, and a near-term breakout setup. If momentum continues, the stock could push above $50 and potentially test the $58 analyst target in the coming weeks.

March 8, 2026
CorMedix Inc. (NASDAQ: CRMD) has emerged as one of the most actively discussed biotechnology stocks following the release of its quarterly earnings on March 5, 2026. While the company reported an earnings-per-share result that fell short of analyst expectations, investor sentiment remains constructive due to reaffirmed growth projections for its flagship product, DefenCath. The market’s reaction today reflects confidence in the company’s revenue trajectory and long-term commercialization strategy.
AI Scorecard OverviewSeveral AI-driven models provide a generally positive outlook for CorMedix, indicating a moderate probability of market outperformance in the near to medium term.

• SST-Score: 6/10 – Classified as Hold, with a projected +5.57% probability of outperforming the market.
• Ensemble Score: 11/15 – Strengthened by the company’s solid cash position of $148.5 million and the announcement of a $75 million share repurchase program.
• LSTM Score: 12/15 – Bullish signal suggesting price stabilization after the initial post-earnings reaction.
• SETUP-AI Score: 7/10 – Identifies a mean-reversion setup, indicating the stock may be oversold following the recent decline.
• Signal: 7/10 – Buy on dips, with investors focusing on the company’s guidance of $300M+ revenue for 2026.
• Sentiment-Score: 8/10 – Sentiment supported by analysts reaffirming price targets between $13 and $18.
• Fundamental-Score: 7/10 – Positive institutional ranking driven by operational profitability and positive EBITDA.

Total AI Score: 76 / 100 – BUY / ACCUMULATE
Earnings Reaction and Financial OutlookCorMedix reported EPS of $0.61, below the consensus estimate of $0.83. Despite the earnings miss, the company delivered strong revenue growth, reporting $128.6 million in revenue, a substantial increase compared to $22.4 million in the same period last year.
More importantly, management reaffirmed its 2026 guidance, projecting:

• Revenue: $300 – $320 million
• EBITDA: $100 – $125 million

This outlook reassures investors about the ongoing commercial scaling of DefenCath and the company’s improving profitability profile.
Strategic Developments and CatalystsTwo key developments are currently driving investor attention:
1. Share Repurchase Program
The company announced a $75 million stock buyback program, widely interpreted by quantitative models and analysts as a strong signal that management believes the current share price undervalues the company’s fundamentals.
2. Upcoming Clinical Catalyst
The next major catalyst is the Phase 3 data release for REZZAYO, expected in Q2 2026. This represents a significant binary event that could materially impact the company’s valuation and future growth prospects.
Trading PerspectiveFollowing the earnings reaction, AI-based models suggest that the recent pullback may present a tactical entry opportunity. The combination of improving revenue growth, strong liquidity, analyst support, and the newly announced buyback provides a supportive backdrop for a potential price recovery.
Suggested swing-trade framework:

• Entry Zone: $6.20 – $6.50
• Short-Term Target: $8.50
• Long-Term Potential: Analyst targets between $13 and $18
• Stop Loss: $5.80 (below recent support)

ConclusionDespite the short-term disappointment from the earnings-per-share miss, the broader investment thesis for CorMedix remains intact. Strong revenue growth, reaffirmed guidance, a substantial share repurchase program, and upcoming clinical catalysts support a constructive outlook. With an AI composite score of 76/100, the stock currently falls within the Buy / Accumulate range, suggesting that the recent dip may represent an attractive opportunity for investors positioning ahead of further operational milestones and clinical developments.

📊 MasTec, Inc. (MTZ) — Technische & Fundamentele Analyse
​Koers: $290.38
Trend: Bullish
Momentum: Licht positief
Risico-score: 6/10

🔥 Trendanalyse

• Nieuwe 52-week high rond $300 → bevestigt sterke uptrend
• Intraday low op $276 → hoge volatiliteit, maar kopers blijven dominant
• Structuur: hogere highs & hogere lows
• Trend is krachtig, maar kortetermijn overextended

➡️ Conclusie technisch: Primary trend = UP

💰 Fundamentele Analyse

• P/E: 69 → relatief duur gewaardeerd
• Market cap: ~$22.9B
• Actief in infrastructuur & energieprojecten (AI-datacenters, power, telecom)
• Structurele groei door Amerikaanse infrastructuurinvesteringen

Ondanks de hoge waardering rechtvaardigt de groeiverwachting deels de premium multiple.

📈 Sentiment & Catalysts

• Positief sectorsentiment (infrastructuur & energie)
• Earnings beat zonder grote gap → gezonde, gecontroleerde stijging
• Geen recente upgrades nodig: momentum komt uit prijsactie

⚖️ Risico

• Hoge waardering → gevoelig voor correcties
• Volatiliteit rond highs
• Marktbreed sentiment blijft bepalend

Risk/Reward blijft aantrekkelijk zolang $270 standhoudt.

🟢 BUY SETUP🎯 StrategiePrimary entry (agressief):
Break & hold boven $300 → momentum continuation trade
Preferred entry (slim geld):
Buy the dip in zone $270 – $280
🛑 Stop-lossOnder $260 (trendbreuk)
🎯 Targets

• $315 (korte termijn momentum target)
• $335–350 (swing target bij voortzetting trend)

📊 EindconclusieTrend is duidelijk bullish.
Fundamenteel duur, maar groei en sector-momentum ondersteunen de waardering.
🔔 Advies:BUY op dip richting $270–280
Momentum traders kunnen kopen bij doorbraak boven $300.
Wil je dat ik hier ook een TradingView-stijl technische onderbouwing (MA, RSI, volume analyse) aan toevoeg zoals je vaak gebruikt voor je X-account?

graag in het engels📊 MasTec, Inc. (MTZ) — Technical & Fundamental AnalysisPrice: $290.38
Trend: Bullish
Momentum: Slightly positive
Risk Score: 6/10

🔥 Trend Analysis

• New 52-week high near $300 → confirms strong uptrend
• Intraday low at $276 → high volatility, but buyers remain in control
• Clear structure of higher highs and higher lows
• Short-term slightly overextended, but trend remains intact

➡️ Technical conclusion: Primary trend = UP

💰 Fundamental Strength

• P/E ratio: 69 → Expensive valuation
• Market cap: ~$22.9B
• Strong positioning in infrastructure, energy, telecom, and AI-related power projects
• Structural growth supported by U.S. infrastructure investments

While valuation is premium, growth outlook justifies part of the multiple.

📈 Sentiment & Catalysts

• Positive sector momentum (infrastructure & energy)
• Earnings beat without a major gap → healthy, controlled price action
• Momentum driven by price strength rather than analyst upgrades

⚖️ Risk Assessment

• High valuation → sensitive to pullbacks
• Elevated volatility near highs
• Broader market sentiment remains a key driver

Risk/Reward remains attractive as long as $270 holds.

🟢 BUY SETUP🎯 StrategyAggressive entry:
Break and hold above $300 → momentum continuation trade
Preferred entry (smart money approach):
Buy the dip in the $270–280 zone
🛑 Stop-LossBelow $260 (trend invalidation level)
🎯 Targets

• $315 (short-term momentum target)
• $335–350 (swing target if trend continues)

📊 Final ConclusionTrend is clearly bullish.
Valuation is elevated, but sector strength and growth momentum support the premium.
🔔 Rating:BUY on dips toward $270–280
Momentum traders can enter on a confirmed breakout above $300.

Travere Therapeutics (TVTX) 💊
Status: Highlighted in green. TVTX reported excellent results yesterday (Feb 19), delivering a strong earnings beat. Revenue increased by 90% year-over-year, driven by their drug sparsentan.
AI Check: The AI score of 8/10 and the SST-rating of 3.8 confirm that the fundamentals are improving.
Strategy: Despite insider selling in December, analysts remain bullish with price targets around $38. The post-earnings dip appears to be a buying opportunity.